AusperBio completes first patient dosing in phase 1 trial of AHB-137 to treat chronic hepatitis B
By, Admin1 min read
Share
Ausper Biopharma Co., Ltd. and AusperBio Therapeutic, Inc. (Together AusperBio) announced the completion of the first cohort dosing in a phase 1 clinical trial evaluating AHB
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
